Skip to main content
. 2012 May 17;106(12):1997–2003. doi: 10.1038/bjc.2012.145

Figure 6.

Figure 6

Association between sorafenib and the MAPK cascade. Sorafenib inhibits the Raf/ERK signalling pathway but not the JNK signalling pathway. The therapeutic efficacy of sorafenib would be limited when JNK is activated in HCCs. Treatment with sorafenib in combination with a JNK inhibitor might open promising therapeutic perspectives.